Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 80.
THEOCLEAR L.A.-130 vs THEOCLEAR-80
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Inhibits phosphodiesterase, increasing cAMP levels, leading to bronchodilation and reduced airway inflammation.
Treatment of asthma (FDA-approved)Treatment of chronic obstructive pulmonary disease (COPD) (off-label)
Treatment of asthmaManagement of chronic obstructive pulmonary disease (COPD)
130 mg orally every 12 hours; extended-release tablet.
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4 (major); also N-demethylation and oxidation. Exhibits non-linear pharmacokinetics.
Primarily hepatic via CYP1A2 and to a lesser extent CYP3A4.
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Approximately 40% bound to plasma proteins, primarily albumin. Binding is reversible and independent of concentration within therapeutic range.
Approximately 40% bound, primarily to albumin.
Vd of 0.3-0.7 L/kg (average 0.5 L/kg) approximates total body water. This indicates extensive distribution into tissues, with higher concentrations in tissues than plasma.
0.3–0.7 L/kg (mean 0.45 L/kg); approximates total body water.
Oral bioavailability of the sustained-release formulation approaches 100% due to complete absorption. However, food can affect absorption rate; with Theoclear L.A.-130, high-fat meals may increase peak concentration and rate of absorption.
Oral: 96–100% (immediate-release); food may affect rate but not extent.
No specific adjustment required; monitor serum concentrations and adjust dose based on clinical response and trough levels.
GFR <30 mL/min: reduce dose by 50% and monitor serum levels. GFR 30-50 mL/min: reduce dose by 25%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels closely.
Child-Pugh Class B or C: reduce dose by 50% and monitor levels; contraindicated in severe hepatic impairment.
Not recommended for children under 6 years; for children 6-12 years: 130 mg once daily initially, titrate based on weight and serum levels (target 5-15 mcg/mL).
Weight-based: 5-10 mg/kg/dose every 6 hours; maximum 300 mg/day for infants <1 year, 600 mg/day for children 1-9 years, 800 mg/day for adolescents.
Initiate at lower end of dosing range (130 mg once daily) and titrate slowly; monitor for toxicity due to reduced clearance.
Start at lowest effective dose; monitor serum levels closely due to reduced clearance; maximum 400 mg/day initially, titrate slowly.
No FDA black box warning.
No FDA black box warning.
["Risk of seizures and arrhythmias at high serum levels (therapeutic range 10-20 mcg/mL)","Monitor serum theophylline levels regularly","Use caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders","May exacerbate arrhythmias; ECG monitoring recommended","Drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin)"]
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with concurrent medications or conditions affecting metabolism.
["Hypersensitivity to theophylline or any component","Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)","Uncontrolled seizure disorder","Active peptic ulcer disease"]
Hypersensitivity to theophylline, active seizure disorder, uncontrolled arrhythmias.
Data Pending Review
Data Pending Review
Avoid high-fat meals which may alter absorption of sustained-release tablets. Limit caffeine intake from coffee, tea, cola, and chocolate. Charcoal-grilled foods may increase clearance. No specific dietary restrictions beyond caffeine moderation; maintain consistent diet to avoid fluctuations in drug levels.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, chocolate, cola). Charcoal-broiled foods may reduce theophylline absorption. High-protein, low-carbohydrate diets may alter clearance. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Theophylline (THEOCLEAR L.A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above baseline. Third trimester use may cause neonatal irritability, tachycardia, and vomiting due to transplacental transfer. Risk of fetal respiratory depression is low at therapeutic maternal levels.
Theophylline (THEOCLEAR-80) is FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies show increased fetal resorptions and delayed skeletal ossification at high doses. Second and third trimesters: possible increased risk of fetal tachycardia and jitteriness due to placental transfer; neonatal theophylline levels approximate maternal levels. Avoid use unless clearly needed.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose. Adverse effects in nursing infants (irritability, sleep disturbance) have been reported. Caution advised; monitor infant for toxicity.
Theophylline excreted into breast milk; milk-to-plasma ratio approximately 0.7. Peak milk levels occur 1-2 hours after dose. Reported infant adverse effects include irritability and jitteriness. Weigh risks vs benefits; monitor infant for signs of theophylline toxicity. Avoid if infant has compromised cardiovascular status.
Pregnancy decreases theophylline clearance (especially third trimester due to decreased hepatic metabolism) and increases volume of distribution. Dose requirements may decrease by 20-30% in later pregnancy. Monitor serum levels and adjust dose to maintain therapeutic range (5-15 mcg/mL). Postpartum clearance returns rapidly (within 2 weeks); dose reduction may be needed to avoid toxicity.
Pregnancy reduces theophylline clearance due to decreased hepatic metabolism and increased volume of distribution, especially in third trimester. Dose adjustments may be required: target serum levels 5-12 mcg/mL. Consider a 20-30% dose reduction in third trimester; monitor levels frequently. Postpartum clearance returns to prepregnancy levels within 2-4 weeks, necessitating dose increase.
Category C
Category C
Theophylline has a narrow therapeutic index (10-20 mcg/mL). Levels >20 mcg/mL increase toxicity risk. Immunoassay cross-reactivity with caffeine and other xanthines may falsely elevate levels. Adjust dose in heart failure, liver disease, and for drug interactions with cimetidine, fluoroquinolones, and macrolides. Smoking induces metabolism requiring dose increase. Sustained-release formulations should not be crushed or chewed.
Theophylline (THEOCLEAR-80) has a narrow therapeutic index (10-20 mcg/mL). Monitor serum levels closely, especially in patients with hepatic impairment, heart failure, or those on drugs that alter its metabolism (e.g., ciprofloxacin, cimetidine, fluvoxamine). Smoking induces metabolism, requiring higher doses. Do not crush or chew extended-release tablets.
Do not crush or chew sustained-release tablets; swallow whole.Take exactly as prescribed; do not double doses if missed.Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.Contact your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.Inform all healthcare providers you are taking this medication.Do not stop suddenly without consulting your doctor.
Take this medication exactly as prescribed, usually every 12 hours for extended-release forms.Do not crush, chew, or break the tablets; swallow them whole.Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.Notify your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.Do not stop taking this medicine abruptly without consulting your doctor.Keep a consistent schedule and do not change brands or formulations without medical advice.